These medicines interrupt particular damage signals, cell-cycle pauses or DNA repair routes. A useful effect depends on the tumour and the interrupted job.
DNA damage response inhibitors interfere with selected signalling, checkpoint or repair functions. ATM, ATR, CHK1, WEE1, DNA-PK and polymerase theta have different, overlapping roles. The relevant question is which function a particular medicine interrupts and whether the sampled tumour currently depends on it. A repair-gene variant, an old genomic scar or prior PARP-inhibitor resistance alone does not establish benefit from another damage-response inhibitor.
Shares CHEK1, DNA replication stress, Synthetic lethality.
Shares POLQ, WEE1, DNA replication stress, ATR.
Shares DNA replication stress, ATR, DNA damage response & homologous recombination, PARP inhibitors.
Shares DNA replication stress, ATR, Synthetic lethality, DNA damage response & homologous recombination.
Shares POLQ, WEE1, DNA replication stress, ATR.
Shares BRCA reversion mutations, Synthetic lethality, DNA damage response & homologous recombination, ATM.
Shares DNA damage response & homologous recombination, Drug resistance (primary and acquired).
Shares HRD genomic scar scores (GIS, LOH, HRDetect), PARP inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/